StockData
GLAUKOS Corp logo

GLAUKOS Corp (GKOS) stock

GKOSNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 7/30219% above fair value
$245.72−0.31 (-0.13%)

Close on Nov 13, 2026Market cap $14.55BP/E –Yield –

Glaukos r&d expenses

Research and development expenses are spending on new products and technology.

Glaukos's R&D Expenses for the twelve months ending Sep 30, 2026 was $201.43M, up 52.3% year over year. For fiscal 2025 it was $150.61M, up 10.4% from the year before. Over ten years it grew 19.6% a year on average. The highest annual figure on record is $150.61M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$150.61M+10.4%
FY2024Dec 31, 2024$136.43M-1.7%
FY2023Dec 31, 2023$138.77M+12.6%
FY2022Dec 31, 2022$123.27M+22.1%
FY2021Dec 31, 2021$101.00M+18.3%
FY2020Dec 31, 2020$85.39M+25.0%
FY2019Dec 31, 2019$68.31M+37.5%
FY2018Dec 31, 2018$49.68M+27.7%
FY2017Dec 31, 2017$38.91M+33.1%
FY2016Dec 31, 2016$29.22M+16.7%
FY2015Dec 31, 2015$25.05M+30.4%
FY2014Dec 31, 2014$19.21M+23.8%
FY2013Dec 31, 2013$15.51M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$30.95M+15.2%
Q2 FY2026Jun 30, 2026$51.30M+40.4%
Q1 FY2026Mar 31, 2026$44.15M+36.4%
Q4 FY2025Dec 31, 2025$75.03M+105.4%
Q3 FY2025Sep 30, 2025$26.86M-22.7%
Q2 FY2025Jun 30, 2025$36.54M+6.1%
Q1 FY2025Mar 31, 2025$32.35M+5.3%
Q4 FY2024Dec 31, 2024$36.53M-1.4%
Q3 FY2024Sep 30, 2024$34.75M+4.3%
Q2 FY2024Jun 30, 2024$34.43M+3.6%
Q1 FY2024Mar 31, 2024$30.73M-12.6%
Q4 FY2023Dec 31, 2023$37.06M+3.5%
Q3 FY2023Sep 30, 2023$33.30M+15.3%
Q2 FY2023Jun 30, 2023$33.23M+4.8%
Q1 FY2023Mar 31, 2023$35.17M+30.9%
Q4 FY2022Dec 31, 2022$35.81M+34.2%
Q3 FY2022Sep 30, 2022$28.87M+0.1%
Q2 FY2022Jun 30, 2022$31.71M+30.7%
Q1 FY2022Mar 31, 2022$26.88M+26.7%
Q4 FY2021Dec 31, 2021$26.68M+25.6%
Q3 FY2021Sep 30, 2021$28.85M+42.1%
Q2 FY2021Jun 30, 2021$24.26M+27.9%
Q1 FY2021Mar 31, 2021$21.22M-14.7%
Q4 FY2020Dec 31, 2020$21.24M+6.1%
Q3 FY2020Sep 30, 2020$20.30M+17.5%
Q2 FY2020Jun 30, 2020$18.97M+11.1%
Q1 FY2020Mar 31, 2020$24.87M+78.6%
Q4 FY2019Dec 31, 2019$20.03M+54.6%
Q3 FY2019Sep 30, 2019$17.28M+30.9%
Q2 FY2019Jun 30, 2019$17.07M+35.4%
Q1 FY2019Mar 31, 2019$13.93M+27.7%
Q4 FY2018Dec 31, 2018$12.96M+23.1%
Q3 FY2018Sep 30, 2018$13.20M+34.6%
Q2 FY2018Jun 30, 2018$12.61M+30.9%
Q1 FY2018Mar 31, 2018$10.91M+22.0%
Q4 FY2017Dec 31, 2017$10.53M+42.2%
Q3 FY2017Sep 30, 2017$9.81M–
Q2 FY2017Jun 30, 2017$9.63M–
Q1 FY2017Mar 31, 2017$8.94M–
Q4 FY2016Dec 31, 2016$7.40M–

More Glaukos figures

See a number that looks wrong?